Tuberculosis and leishmanisis have been prime concern for health-care establishments worldwide among the various infectious diseases especially in the low- and middle-income developing countries. As per WHO fact-sheet, 8.6 million people fell ill with TB and 1.3 million died from TB in 2012 whereas an estimated 1.3 million new cases and 20000 to 30000 deaths occur annually through leishmaniasis.1 The increasing instances of resistance towards the available drugs for chemotherapy of these disease raised the necessity to search for new drug candidates. The remarkable potential of the a-aminophosphonate moiety in medicinal chemistry with diverse biological activities2 have impressed us for biological evaluation of various structurally diverse a-aminophosphhonates (a-sulfonamidophosphonates, bis-a-aminophosphonates ) as antileishmanial and anti-tuberculosis agent. The primary findings reveal a-aminophosphonates as novel antileishmanial chemotypes 3and further extended result of several new compounds for these infectious diseases have been obtained. These observations may provide new therapeutic lead(s) for these infectious diseases .References: 1. (a)http://www.who.int/mediacentre/factsheets/fs104/en/ (b) http://www.who.int/mediacentre/factsheets/fs375/en/2. (a) Galezowska, J.; Gumienna-Kontecka, E. Coord. Chem. Rev. 2012  , 256, 105�124 (b) Bhattacharya, A. K.; Rana, K. C.; Pannecouque, C.; De Clercq, E. ChemMedChem, 2012  , 7, 1601-1611. (c) Mucha, A.; Kafarski, P.; Berlicki, L. J. Med. Chem. 2011  , 54, 5955-5980.3. Bhagat, S.; Shah, P.; Garg, S. K.; Mishra, S.; Kaur, P.; Singh, S.; Chakraborti, A. K. Med. Chem. Commun.  , 2014  , Accepted Manuscrip; DOI: 10.1039/C3MD00388D

a-Sulfonamidophosphonates and bis-a-aminophosphonates: New leads towards          infectious disease chemotherapy

248th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.